Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial
Michael Berk, Bruno Agustini, Robyn L Woods, Mark R Nelson, Raj C Shah, Christopher M Reid, Elsdon Storey, Sharyn M Fitzgerald, Jessica E Lockery, Rory Wolfe, Mohammadreza Mohebbi, Seetal Dodd, Anne M Murray, Nigel Stocks, Paul B Fitzgerald, Catherine Mazza, John J McNeil
MOLECULAR PSYCHIATRY | SPRINGERNATURE | Published : 2021
Late-life depression is common and often inadequately managed using existing therapies. Depression is also associated with increased markers of inflammation, suggesting a potential role for anti-inflammatory agents. ASPREE-D is a sub-study of ASPREE, a large multi-centre, population-based, double-blind, placebo-controlled trial of aspirin vs placebo in older Australian and American adults (median follow-up: 4.7 years) of whom 1879 were depressed at baseline. Participants were given 100 mg daily dose of aspirin or placebo. Depressive symptoms were assessed annually using the validated, self-rated short version of the Center for Epidemiological Studies Depression scale. There was a significant..View full abstract
Awarded by National Institute on Aging
Awarded by National Health and Medical Research Council of Australia
Awarded by NHMRC Senior Principal Research Fellowship
This paper was supported by a grant (U01AG029824) from the National Institute on Aging and the National Cancer Institute at the National Institutes of Health, by grants (1081901, 334047 and 1127060) from the National Health and Medical Research Council of Australia. MB is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072).